LongevityTech.fund

VCMatch tracks LongevityTech.fund as an investor focused on Biotech, Digital Health, and AI/ML companies, Seed and Series A rounds, and Europe, United States, and Global markets. Upload your deck to compare your startup against the full private matching profile.

Check Size

Not specified

Stages

Seed, Series A

Focus Areas

Biotech, Digital Health, AI/ML

Geography

Europe, United States, and Global

Investment Thesis

The firm positions longevity investing as both a scientific and moral mission: they state that “extending healthy human lifespan is not just a scientific possibility, but an ethical imperative,” and they invest in “breakthrough technologies that target the fundamental mechanisms of aging” to create healthier, longer lives. They combine long-term, patient capital with a science-first, disciplined approach—aiming not only for clinical outcomes but to “transform how society approaches aging, creating sustainable healthcare systems, and unlocking human potential across extended lifespans.”

To execute this, they emphasize rigorous, translational support: in-house PhDs, a network of 100+ KOLs, and a unique infrastructure (centers in Europe and the US providing human studies, CRO services, and early clinical validation) to accelerate laboratory discoveries into products and consumer-facing validation.

Is LongevityTech.fund right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

LongevityTech.fund is most relevant for founders raising Seed and Series A rounds in Biotech, Digital Health, AI/ML, and Data Infrastructure, especially across Europe, United States, and Global.

Focus statement

They focus on "Therapeutics, platforms & tools, data & AI, and prevention technologies that address the root causes of aging," deploying capital primarily into "Early-stage investments with selective focus on companies demonstrating scientific rigor and market potential."

Value Add

Active specialist in longevity since 2019, "managing one of the largest longevity portfolios globally" and "fostering strong syndication with tier-1 venture partners."
Science-first diligence supported by in-house PhDs and an "extensive network of 100+ Key Opinion Leaders (KOLs) across geroscience, biomarkers, and translational medicine."
Built ecosystem and infrastructure with centers in Europe and the US that "provides human studies, CRO services, and a direct pathway to early clinical validation."
Platform companies that "serve as a consumer testing ground and engagement layer"—enabling early market and user validation alongside clinical translation.
Patient-capital mindset with "strong governance principles," supporting long-duration scientific development rather than short-term exits.